INTERVIEW: Oraya doesn't see threat from new AMD drugs
This article was originally published in Scrip
US medical device company Oraya Therapeutics is ramping up commercialization of its radiotherapy product for age-related macular degeneration (AMD) – a treatment that looks set to disrupt a market currently dominated by drug giants Novartis and Roche with their anti-VEGF drug Lucentis (ranibizumab). Even the advent of the newer AMD drugs, such as Regeneron's approved anti-VEGF therapy Eylea (aflibercept injection) and Ophthotech's investigational platelet-derived growth factor (PGDF) inhibitor Fovista, leaves Oraya unperturbed.
You may also be interested in...
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.